Tauklarify is a new PET imaging tracer, and it answers a narrower question than amyloid PET does. Getting a Tauklarify scan tells a clinician whether tau tangles are present in the brain, not whether someone has Alzheimer's disease, and for people with mild cognitive impairment (MCI) the result needs to be read alongside other evidence rather than taken as a final answer.
The FDA approved Tauklarify (florquinitau F18, also known as MK-6240) on August 14, 2026, for PET imaging in adults with cognitive impairment, including MCI, who are being evaluated for Alzheimer's disease, according to Lantheus's investor announcement. The scan detects tau neurofibrillary tangles, one of the two hallmark proteins of Alzheimer's pathology. That approval is real and specific, but the label and the data behind it both contain limits that matter most for someone at the MCI stage, where tau pathology is often just beginning to accumulate.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the original argument from NIH — Use this page to read the original argument in context.
- Read the original research from NIH — Use this page to review the original research.
Table of Contents
- What Tauklarify Actually Detects
- Why the Label Itself Warns Against a Simple Yes-or-No Reading
- Why Amyloid PET and Tau PET Aren't Substitutes for Each Other
- Where the MCI-Specific Evidence Gets Thin
- What to Actually Do With a Tauklarify Result
- Frequently Asked Questions
What Tauklarify Actually Detects
Tauklarify binds to tau tangles, the twisted protein threads that build up inside neurons as Alzheimer's progresses. A PET scan using this tracer lights up regions where tau has accumulated, giving a visual and quantifiable picture of how much tangle pathology exists and where it sits in the brain. This is different from amyloid PET, which detects amyloid plaques, the other hallmark Alzheimer's protein that builds up outside neurons.
The two pathologies accumulate on different timelines and in different patterns, which is why regulators approved separate tracers for each one rather than treating them as interchangeable tests. Tauklarify's approval covers only Alzheimer's evaluation. It is not approved to assess other tauopathies, meaning diseases that also involve tau buildup but aren't Alzheimer's, such as frontotemporal dementia, according to Lantheus's announcement. A Tauklarify result says nothing about whether cognitive symptoms stem from one of those other conditions.
Why the Label Itself Warns Against a Simple Yes-or-No Reading
Tauklarify's own prescribing information states that a negative scan does not necessarily rule out tau pathology, and a positive scan does not necessarily confirm Alzheimer's disease has been proven on tissue examination, as reported by Practical Neurology's coverage of the label. The label instructs clinicians to pursue further evaluation whenever clinical uncertainty remains after the scan. That caveat isn't boilerplate. In the two pivotal studies that supported approval, covering 279 and 338 participants including 157 people with MCI, readers agreed with the reference diagnosis on positive scans only 80–88% of the time in one study and as low as 68–82% in the other, according to NeurologyLive's reporting on the FDA approval.
Negative scans fared better, with agreement between 93% and 99%. In practical terms, the scan is considerably more reliable at telling someone they likely don't have significant tau pathology than at confirming they do. That asymmetry means a positive result carries more built-in uncertainty than a negative one. A clinician who orders this scan for someone with MCI needs to weigh a "positive" reading against the real chance it's one of the roughly one-in-five to one-in-three cases where readers disagreed with the confirmed diagnosis.
Why Amyloid PET and Tau PET Aren't Substitutes for Each Other
Amyloid PET and tau PET answer different clinical questions, and studies bear that out directly. A memory-clinic study found that a negative amyloid PET scan changed a patient's diagnosis more often than a negative tau PET scan did, because amyloid PET has a stronger track record for ruling Alzheimer's out, according to a peer-reviewed study on PMC. If the clinical goal is to exclude Alzheimer's as a cause of symptoms, amyloid PET has historically done that job more decisively than tau PET. Tau PET's real strength lies elsewhere: staging disease severity rather than simply detecting presence or absence.
Regional patterns of tau uptake on PET correspond to Braak stages, the standard neuropathologic scale for how far Alzheimer's has progressed through the brain, according to a UC Berkeley research summary. Widespread cortical tau seen on PET is most clinically meaningful when amyloid PET is also positive, since the two findings together paint a fuller picture than either scan alone. This is why a tau PET result in isolation can mislead someone into treating it as the whole story. It was designed to complement amyloid findings, not replace them, and reading it as a standalone verdict skips the context that gives it meaning.
Where the MCI-Specific Evidence Gets Thin
Tauklarify's diagnostic performance was established largely by comparing amyloid-PET-negative, cognitively unimpaired people against amyloid-PET-positive, cognitively impaired people, a contrast wider than MCI itself, which limits how confidently the results extend to people at the early or intermediate stage, according to PharmTech's analysis of the approval. MCI sits in between those two extremes, and a test validated mostly on clearer-cut cases may not perform identically at that earlier, more ambiguous stage.
A 2026 head-to-head study in The Lancet compared Tauklarify's tracer (MK-6240) against flortaucipir (Tauvid), the previously approved tau tracer. MK-6240 showed higher diagnostic accuracy in brain regions affected at advanced disease stages, but the two tracers agreed on tau-stage classification only 30% of the time among participants at the earliest tau stage, according to the Lancet study data archived on PMC. That earliest stage is exactly where most people with MCI are likely to fall, which means two legitimate, FDA-approved tau tracers can disagree about staging in the population that would most want a clear answer.
- MCI-specific validation data is thinner than the overall approval data suggests.
- Tracer-to-tracer agreement is weakest at the earliest tau stage, the one most relevant to MCI.
- A result at this stage is a data point for a clinician to weigh, not a standalone diagnosis.
What to Actually Do With a Tauklarify Result
Because the label warns against treating either a positive or negative result as conclusive, and because head-to-head data show the weakest tracer agreement at exactly the early stage most MCI patients occupy, a Tauklarify result is best interpreted alongside amyloid PET, blood or cerebrospinal fluid biomarkers, and a clinician's broader judgment, rather than as a standalone yes-or-no answer. This synthesis follows directly from the label caveats reported by Practical Neurology and the tracer concordance data from the HEAD study.
Before agreeing to a Tauklarify scan, or after receiving a result, these are useful questions to raise with a neurologist or memory-clinic team: A negative scan paired with a negative amyloid PET lowers the likelihood of Alzheimer's-driven decline meaningfully more than either test alone. A positive tau scan paired with a positive amyloid scan carries more weight than a positive tau result by itself, consistent with the staging value tau PET adds on top of amyloid PET rather than instead of it.
- Has amyloid PET or a biomarker test (blood or CSF) already been done, or is one planned alongside this scan?
- If the result is positive, what Braak-stage region does the uptake fall in, and does that change management now or only later?
- If the result is negative, does that rule out tau pathology, or just mean none was detected at a level this scan can reliably catch?
- Is the care team treating this as one input among several, or as the determining test?
Frequently Asked Questions
Can Tauklarify diagnose Alzheimer's disease by itself?
No. The label states a positive scan does not necessarily confirm histopathologically proven disease, so clinicians are directed to pursue further evaluation when uncertainty remains, as reported by Practical Neurology.
Does a negative Tauklarify scan rule out tau pathology?
Not necessarily. The label explicitly states a negative scan does not necessarily rule out tau pathology, even though negative percent agreement in the pivotal studies ranged from 93% to 99%, according to NeurologyLive.
Is Tauklarify useful for diagnosing frontotemporal dementia or other tauopathies?
No. It is approved only for Alzheimer's disease evaluation, and Lantheus's announcement specifies it is not approved to evaluate non-Alzheimer's tauopathies.
You Might Also Like
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
